Founded with a mission to revolutionize healthcare through digital innovation, metaMe Health focuses on developing FDA-cleared prescription digital therapeutics (PDTs) for gastrointestinal conditions. The company's vision is to leverage the power of the mind to manage chronic disorders and pain without relying on traditional medications. Their primary product offerings are software applications designed to train the brain, enabling patients to manage their conditions via smartphones or tablets, providing a convenient and accessible treatment option.

Notable figures associated with metaMe Health include key investors and advisors from the digital health and medical technology sectors. The company has achieved significant milestones, including obtaining FDA clearance for its digital therapeutics, which underscores its commitment to clinical efficacy and regulatory compliance. By offering innovative, non-pharmacological treatment options, metaMe Health has made a substantial impact on the lives of patients with chronic gastrointestinal conditions, promoting a shift towards more holistic and patient-centric healthcare solutions.